Targeted delivery of siRNA against hepatitis B virus by preS1 peptide molecular ligand

Hepatology Research

Volumn 44, Issue 8, 2014, Pages 897-906

  Huang, Wenjuan ^a   Li, Xia ^a   Yi, Min ^a   Zhu, Sufen ^a   Chen, Weixian ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Molecular ligand; preS1; RNA interference

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; PEPTIDE; PRES1 PEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HEPATITIS B; HEPATITIS B VIRUS; HEPG2 CELL LINE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA TRANSPORT; VIRAL GENE DELIVERY SYSTEM;

EID: 84904767744     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12189     Document Type: Article

References (32)

1. Tanaka M, Katayama F, Kato H etal. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011; 21: 401-416.
2. Ying RS, Zhu C, Fan XG etal. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Antiviral Res 2007; 73: 24-30.
3. Chang JM, Huan KL, Yuan TT etal. The anti-hepatitis B virus activity of Boehmeria nivea extract in HBV-viremia SCID mice. Evid Based Complement Alternat Med 2010; 7: 189-195.
4. Motavaf M, Alavian SM. RNA interference: a promising approach for the treatment of viral hepatitis. Hepat Mon 2012; 12: 7-8.
5. de Vries W, Haasnoot J, van der Velden J etal. Increased virus replication in mammalian cells by blocking intracellular innate defense responses. Gene Ther 2008; 15: 545-552.
6. Guo W, Chen W, Yu W etal. Small interfering RNA-based molecular therapy of cancers. Chin J Cancer 2013; doi: 10.5732/cjc.012.10280.
7. Petersen J, Dandri M, Mier W etal. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341.
8. Deng Q, Zhai JW, Michel ML etal. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J Virol 2007; 81: 4244-4254.
9. Dash S, Rao KV, Panda SK etal. Receptor for Pre-Sl (21-47) component of hepatitis B virus on the liver cell: role in virus cell interaction. J Med Virol 1992; 37: 116-121.
10. Falnes PØ, Wesche J, Olsnes S. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 2001; 4: 4349-4358.
11. Futaki S, Suzuki T, Ohashim W etal. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001; 23: 5836-5840.
12. Federica S, May C, Morris F etal. Peptide carrier for delivering siRNA into mammalian cells. 2009: US: Patent 7514530.
13. Tian Y, Kuo CF, Chen WL etal. Enhancement of hepatitis B virus replication by androgen and its receptor in mice. J Virol 2012; 86: 1904-1910.
14. Morrissey DV, Lockridge JA, Shaw L etal. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007.
15. Rozema DB, Lewis DL, Wakefield DH etal. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007; 104: 12982-12987.
16. Carmona S, Jorgensen MR, Kolli S etal. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 2009; 6: 706-707.
17. Uno Y, Piao W, Miyata K etal. High-density lipoprotein facilitates in vivo delivery of α-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther 2011; 22: 711-719.
18. Bramsen JB, Kjems J. Development of therapeutic-grade small interfering RNAs by chemical engineering. Front Genet 2012; 3: 154.
19. Kim SI, Shin D, Choi TH etal. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2007; 15: 1145-1152.
20. Sato Y, Murase K, Kato J etal. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagenspecific chaperone. Nat Biotechnol 2008; 26: 431-442.
21. Bedi D, Gillespie JW, Petrenko VA Jr etal. Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol Pharm 2013; 10: 551-559.
22. Alvarez-Erviti L, Seow Y, Yin H etal. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29: 341-345.
23. Kang JH, Tachibana Y, Obika S etal. Efficient reduction of serum cholesterol by combining a liver-targeted gene delivery system with chemically modified apolipoprotein B siRNA. J Control Release 2012; 163: 119-124.
24. Argnani R, Boccafogli L, Marconi PC etal. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Ther 2004; 11: 1087-1098.
25. Meier A, Mehrle S, Weiss TS. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 2013; 58: 31-42.
26. He D, Yang H, Lin Q, Huang H. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. Int J Biochem Cell Biol 2005; 37: 192-205.
27. Jablonski AE, Kawakami T, Ting AY etal. Pyrenebutyrate leads to cellular binding, not intracellular delivery, of polyarginine-quantum dots. J Phys Chem Lett 2010; 1: 1312-1315.
28. Lu YP, Guo T, Wang BJ, Dong JH etal. Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients. World J Gastroenterol 2008; 14: 3490-3496.
29. Murata M, Narahara S, Umezaki K, Toita R etal. Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages. Int J Nanomedicine 2012; 7: 4353-4362.
30. Brezillon N, Brunelle MN, Massinet H etal. Antiviral activity of bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID. PLoS ONE 2011; 6: e25096. doi: 10.1371/journal.pone.0025096.
31. Dandri M, Volz TK, Lütgehetmann M etal. Animal models for the study of HBV replication and its variants. J Clin Virol 2005; 34: S54-62.
32. Wentworth PA, Vitiello A, Sidney J etal. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 1996; 26: 97-101.